Journal Watch · Frontiers in Immunology · 2026
Nuclear localization of Toll/interleukin-1 receptor domain-containing adaptor protein reveals a previously unrecognized role in hepatic stellate cell activation.
Importantly, silencing of TIRAP in LX-2 significantly reduced the nuclear translocation and expression of fibrotic markers (such as <i>α-SMA</i> and <i>collagen</i>) in HSCs, suggesting a key role of nuclear TIRAP in driving fibrogenesis.<h4>Conclusion</h4>Overall, these findings reveal a novel role for TIRAP beyond cytoplasmic signaling, suggesting potential nuclear functions that may regulate transcriptional programs driving inflammation and fibrosis.
TL;DR
Importantly, silencing of TIRAP in LX-2 significantly reduced the nuclear translocation and expression of fibrotic markers (such as <i>α-SMA</i> and <i>collagen</i>) in HSCs, suggesting a key role of nuclear TIRAP in driving fibrogenesis.<h4>Conclusion</h4>Overall, these findings reveal a novel role for TIRAP beyond cytoplasmic signaling, suggesting potential nuclear functions that may regulate transcriptional programs driving inflammation and fibrosis.
Key findings
- Importantly, silencing of TIRAP in LX-2 significantly reduced the nuclear translocation and expression of fibrotic markers (such as <i>α-SMA</i> and <i>collagen</i>) in HSCs, suggesting a key role of nuclear TIRAP in driving fibrogenesis.<h4>Conclusion</h4>Overall, these findings reveal a novel role for TIRAP beyond cytoplasmic signaling, suggesting potential nuclear functions that may regulate transcriptional programs driving inflammation and fibrosis.
What they did
Immunofluorescence and immunoblotting were performed to check TIRAP's expression. siRNA was used for TIRAP silencing to monitor its significant activity. mRNA expression for pro-fibrotic markers was checked via qRT-PCR.<h4>Results</h4>We demonstrated for the first time, nuclear translocation of TIRAP under alcoholic conditions. Confocal microscopy and nuclear-cytoplasmic fractionation confirmed TIRAP enrichment in the nucleus.
Full abstract (original)
Background: <h4>Background</h4>The Toll/interleukin-1 receptor domain-containing adaptor protein (TIRAP) is a key adaptor in Toll-like receptor signaling, classically functioning as a cytoplasmic bridging adaptor for Myeloid differentiation primary response 88 (MyD88) recruitment. While its role in inflammatory signaling is well established, its contribution to alcohol-induced liver fibrosis remains unclear.<h4>Methods</h4>We used lipopolysaccharide (LPS) and ethanol-stimulated hepatic stellate cells (LX-2) for <i>in vitro</i> analysis.
What they did: Immunofluorescence and immunoblotting were performed to check TIRAP's expression. siRNA was used for TIRAP silencing to monitor its significant activity. mRNA expression for pro-fibrotic markers was checked via qRT-PCR.<h4>Results</h4>We demonstrated for the first time, nuclear translocation of TIRAP under alcoholic conditions. Confocal microscopy and nuclear-cytoplasmic fractionation confirmed TIRAP enrichment in the nucleus.
Results & conclusions: Importantly, silencing of TIRAP in LX-2 significantly reduced the nuclear translocation and expression of fibrotic markers (such as <i>α-SMA</i> and <i>collagen</i>) in HSCs, suggesting a key role of nuclear TIRAP in driving fibrogenesis.<h4>Conclusion</h4>Overall, these findings reveal a novel role for TIRAP beyond cytoplasmic signaling, suggesting potential nuclear functions that may regulate transcriptional programs driving inflammation and fibrosis.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1870084 · PubMed 42698655.
Why it matters for pharma & biotech
- Directly relevant to teams in mRNA / delivery technology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: mRNA / delivery technology
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
Importantly, silencing of TIRAP in LX-2 significantly reduced the nuclear translocation and expression of fibrotic markers (such as <i>α-SMA</i> and <i>collagen</i>) in HSCs, suggesting a key role of nuclear TIRAP in driving fibrogenesis.<h4>Conclusion</h4>Overall, these findings reveal a novel role for TIRAP beyond cytoplasmic signaling, suggesting potential nuclear functions that may regulate transcriptional programs driving inflammation and fibrosis.
What type of study is this?
It is a in-vitro / cell study, published in Frontiers in Immunology in 2026. Immunofluorescence and immunoblotting were performed to check TIRAP's expression.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1870084. PubMed ID: 42698655. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/nuclear-localization-of-toll-interleukin-1-receptor-domain-containing-ad-870084/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides